Plasmid-mediated Quinolone Resistance in Salmonella enterica, United Kingdom

1. World Health Organization. Global strategy for containment of antimicrobial resistance [cited 2006 Nov 10]. Geneva: The Organization; 2001. Available from http://www.who.int/drugresistance/en 2. Bartoloni A, Pallecchi L, Benedetti M, Fernandez C, Vallejos Y, Guzman E, et al. Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia. Emerg Infect Dis. 2006;12:907–13. 3. Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, et al. Rapid dissemination and diversity of CTX-M extended-spectrum β-lactamase genes in commensal Escherichia coli from healthy children from low-resource settings of Latin America. Antimicrob Agents Chemother; 2007;51:2720–5 4. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. 2006;119:S20–8. 5. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6:629–40. 6. Johnson JR, Kuskowski MA, Menard M, Gajewski A, Xercavins M, Garau J. Similarity between human and chicken Escherichia coli isolates in relation to ciprofl oxacin resistance status. J Infect Dis. 2006;194:71–8. 7. Lautenbach E, Fishman NO, Metlay JP, Mao X, Bilker WB, Tolomeo P, et al. Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fl uoroquinolones: results from a large hospital-based surveillance initiative. J Infect Dis. 2006;194: 79–85. 8. Rodriguez-Baño J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum beta-lactamaseproducing organisms. Clin Infect Dis. 2006;42:935–7. 9. Ben-Ami R, Schwaber MJ, Navon-Venezia S, Schwartz D, Giladi M, Chmelnitsky I, et al. Infl ux of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis. 2006;42:925–34. 10. Collignon P, Angulo FJ. Fluoroquinolone-resistant Escherichia coli: food for thought. J Infect Dis. 2006;194:8–10.